Skip to main content
Gentian Diagnostics ASA logo

Gentian Diagnostics ASA — Investor Relations & Filings

Ticker · GENT ISIN · NO0010748866 LEI · 5967007LIEEXZXHNM861 OL Manufacturing
Open in API
Filings indexed 468 across all filing types
Latest filing 2021-12-16 Report Publication Anno…
Country NO Norway
Listing OL GENT

About Gentian Diagnostics ASA

https://www.gentian.com/

Gentian Diagnostics ASA is a medical diagnostics company that develops, manufactures, and markets innovative in vitro diagnostic (IVD) reagents. The company specializes in turbidimetric immunoassays designed for open clinical chemistry platforms, aiming to enhance laboratory efficiency and support better clinical treatment decisions. Its portfolio and pipeline of diagnostic tests address biomarkers in high-impact medical areas, including kidney disease, cardiac disease, inflammation, and infection. Key products include assays for Cystatin C, NGAL, and Calprotectin. In addition to its human diagnostics portfolio, the company provides diagnostic solutions for the veterinary market. Gentian serves a global customer base through original equipment manufacturer (OEM) partners, distributors, and healthcare providers.

Recent filings

Filing Released Lang Actions
Financial calendar
Report Publication Announcement Classification · 100% confidence The document text is titled 'Financial calendar' and lists scheduled dates for various corporate events throughout 2021 and 2022, including 'Quarterly Report', 'Half-yearly Report', 'Annual Report', and 'Annual General Meeting'. This document is purely an announcement of future dates for corporate reporting and meetings, not the reports or meeting materials themselves. Since there is no specific category for a 'Financial Calendar', and it is an announcement about future corporate events/reports, the most appropriate classification is Report Publication Announcement (RPA) if it were announcing the publication of a specific report, or Regulatory Filing (RNS) as a general announcement. Given the nature of listing future dates for various mandatory reports and meetings, it functions as a general corporate update. However, since it is a schedule of future events rather than an announcement of a *past* or *imminent* publication of a specific report, and it doesn't fit any other specific category (like AGM-R or ER), RNS (Regulatory Filings - general fallback) is the safest classification for a calendar announcement.
2021-12-16 English
Completed development of SARS Cov-2 antibody assay
Regulatory Filings Classification · 99% confidence The document is a short press release dated December 16, 2021, announcing the completion of technical development for a new SARS-Cov-2 antibody assay and outlining next steps (CE-marking, production scale-up, expected commercial launch in Feb 2022). It details a product development milestone and future commercial plans, rather than releasing periodic financial results (ER/IR), providing detailed financial supplements (XLSX), or announcing management/board changes (MANG). Since it is a specific announcement about a product/development milestone that doesn't fit into the primary financial reporting categories, and it is not a general regulatory filing fallback (RNS), it best fits the category for updates on financing, capital structure, or significant corporate activities that aren't explicitly covered elsewhere. However, given the options, this is a general corporate update about a product development milestone. It is not a standard regulatory filing like 10-K or IR. It is most closely related to a general corporate announcement. Since there is no specific 'Product Development Update' category, and it is not a formal financial report, it falls under the general 'Regulatory Filings' (RNS) as a miscellaneous announcement, or potentially 'Capital/Financing Update' (CAP) if the development is seen as a precursor to future revenue generation, but RNS is the safer fallback for non-standard announcements. Given the context of a press release announcing a major operational milestone, RNS (Regulatory Filings/General Announcement) is the most appropriate general category.
2021-12-16 English
Gentian Diagnostics presents at the DNB Nordic Healthcare Conference
Investor Presentation Classification · 98% confidence The document is a presentation titled 'DNB Nordic Healthcare Conference 16 December 2021' featuring the CEO of Gentian Diagnostics ASA. It contains slides detailing the company's strategy, management team, product portfolio, market size, and Q3 2021 financial highlights (Sales: NOK 17.2m, EBITDA: NOK -4.2m). This structure—a presentation given at a specific conference, summarizing recent performance and future outlook—is characteristic of an Investor Presentation (IP). It is not a formal regulatory filing like a 10-K, nor is it just a brief announcement of results (ER) or a transcript of a call (CT).
2021-12-16 English
Gentian Diagnostics presents at the DNB Nordic Healthcare Conference
Report Publication Announcement Classification · 99% confidence The document is very short (591 characters) and announces that the CEO will present at a conference and explicitly states, 'Please find the presentation attached.' This structure—a brief announcement stating that presentation materials are available—strongly indicates that the document itself is an announcement about the presentation, not the full presentation or a major regulatory filing. Since the presentation is related to company activities and investor relations, and given the options, the most fitting category for an announcement regarding a presentation or event material is often a general Regulatory Filing (RNS) or potentially an Investor Presentation (IP) if the announcement was more detailed. However, following Rule #2 (MENU VS MEAL), since this is an announcement that the presentation is attached, it fits the pattern of a Report Publication Announcement (RPA) or a general Regulatory Filing (RNS). Given that it is an announcement about a presentation at a specific conference, RNS is a safe fallback for non-standard announcements, but RPA is specifically for announcing the publication of reports/materials. Since the material being announced is a 'company presentation,' RPA is the most precise fit for announcing the availability of investor-related materials.
2021-12-16 English
Share capital increase registered - Correction*
Share Issue/Capital Change Classification · 98% confidence The document explicitly discusses a 'Share capital increase registered' and references a prior notice regarding a 'share issue in connection with an employee share purchase program (ESPP)'. It details the number of new shares issued and the resulting new registered share capital (15,422,350 shares). This directly relates to changes in the company's capital structure via share issuance, which aligns perfectly with the definition of 'Share Issue/Capital Change' (SHA). Although it is a short notice, the content is substantive regarding the capital change itself, not just announcing the publication of a larger report.
2021-12-10 English
Share capital increase registered
Share Issue/Capital Change Classification · 98% confidence The document explicitly states "Share capital increase registered" and details the issuance of 10,641 new shares in connection with an employee share purchase program (ESPP), concluding with the new registered share capital amount. This directly relates to a change in the company's capital structure via new share issuance. This aligns perfectly with the definition for Share Issue/Capital Change (SHA). The document length is short, but it is the primary announcement of the capital change itself, not an announcement *about* a report, making SHA more specific than RPA or RNS.
2021-12-09 English

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.